Actinium Pharmaceuticals (NYSE:ATNM) Shares Up 4.5% – Still a Buy?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM)’s share price shot up 4.5% during mid-day trading on Monday . The company traded as high as $1.16 and last traded at $1.15. 94,159 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 169,683 shares. The stock had previously closed at $1.10.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ATNM. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Actinium Pharmaceuticals in a report on Friday, November 15th. StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, Stephens reiterated an “overweight” rating and set a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

Actinium Pharmaceuticals Stock Down 7.1 %

The firm’s 50 day simple moving average is $1.24 and its 200-day simple moving average is $1.59. The company has a market capitalization of $36.50 million, a PE ratio of -0.84 and a beta of 0.13.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ATNM. Creative Financial Designs Inc. ADV lifted its position in shares of Actinium Pharmaceuticals by 183.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock worth $120,000 after purchasing an additional 41,250 shares in the last quarter. Interchange Capital Partners LLC acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth $37,000. Los Angeles Capital Management LLC acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth $322,000. Wellington Management Group LLP acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth $112,000. Finally, XTX Topco Ltd acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth $268,000. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).